Celltrion (068270) Q3 2024 earnings summary

Executive summary

• Achieved consolidated 3Q24 sales of KRW 881.9bn, up 31.2% year-over-year and 0.8% sequentially, driven by strong global biologics growth.

• Operating profit reached KRW 207.7bn in 3Q24, up 186.5% sequentially but down 22.4% year-over-year; OP margin improved to 23.6% due to better COGS and lower PPA amortization.

• Cumulative 3Q24 sales surpassed 2023 annual sales, with 2024 full-year sales expected to exceed KRW 3.5tn guidance.

• Achieved consolidated sales of 2,493.7 billion KRW and operating profit of 295.6 billion KRW for the first nine months of 2024, with an operating margin of 11.9%.

• Completed the merger with Celltrion Healthcare, integrating development, production, and sales for enhanced efficiency and market reach.

Financial highlights

• Biologics sales rose 75.2% year-over-year to KRW 810.0bn, led by Remsima SC, Yuflyma, and Vegzelma; non-biologics sales fell 65.8% due to deferred CMO and DP service revenue.

• Net profit for 3Q24 was KRW 84.1bn, with a net margin of 9.5%.

• Operating profit: 295.6 billion KRW, net profit: 183.3 billion KRW, basic EPS: 900 KRW for the first nine months of 2024.

• Cash and cash equivalents at period end: 972.7 billion KRW.

• Gross profit margin improved to 52.5% in 3Q24 from 42.1% in 2Q24; OP margin rebounded to 23.6% from 8.3% sequentially.

Outlook and guidance

• 2024 annual sales are anticipated to surpass KRW 3.5tn, with continued margin improvement expected as high-cost inventory is digested and new, lower-cost production ramps up.

• Continued expansion of biosimilar portfolio with multiple new approvals and launches expected in the US, EU, and Asia.

• Ongoing investments in R&D and production capacity to support pipeline growth and global market penetration.

• Focus on direct sales expansion and operational synergies post-merger to drive profitability.

• OP margin is projected to remain in the mid-20% range in upcoming quarters.